explore -WSS

explore

author：comprehensive 2025-10-02 22:15:28 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： How a small hospital in rural Puerto Rico survived Hurricane Maria

hotspot

WSS

The creative science of coining drug names

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Novel spinal cord stimulator treats paralysis without surgery

As billionaires fund anti

focus

explore

focus

How one medical school became remarkably diverse

Primary care doctor shortage won't be solved by free med school tuition

In Memoriam: Notable people who died in 2023

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Medicare details structure of new drug price negotiation program

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

New air purifier tech could be key to improving indoor air quality

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Dobbs anniversary: the lost opportunity of abortion as health care

HHS's proposed rule does nothing to address the climate crisis

knowledge

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Sepsis can kill a child within hours. Here's how hospitals are fighting back

As billionaires fund anti

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Brain technologies pose threats that are all too real, experts warn

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

knowledge

hotspot

focus

Wikipedia